Project Title: AI‑driven first‑in‑class antibiotics and novel integrated end‑to‑end solution for H. pylori

**The global urgent threats of antimicrobial resistance, and _H. pylori_ – a Group 1 carcinogen linked to 90% of gastric cancers, with treatment resistance and no dedicated preventive oral care.** **We offer novel antibiotics that act on a new bacterial target sites and show no resistance, alongside the world’s first _H. pylori_‑specific oral care range proven to inhibit the bacterium,** **complemented by high‑accuracy diagnostics and therapies.** **Key advantages of our novel antibiotics include low toxicity, validated in vivo efficacy, strong patent protection.  For _H. pylori_ Nobel laureate collaboration, and a complete prevention‑diagnosis‑treatment pipeline, all aim at reducing antibiotic resistance and gastric cancer risk.**